Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, May 8, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Rachel Vatnsdal Maintained (ADPT) at Buy with Decreased Target to $5 on, May 8th, 2024
Rachel Vatnsdal of JP Morgan, Maintained "Adaptive Biotechnologies Corporation" (ADPT) at Buy with Decreased Target from $8 to $5 on, May 8th, 2024.
Rachel has made no other calls on ADPT in the last 4 months.
There are 2 other peers that have a rating on ADPT. Out of the 2 peers that are also analyzing ADPT, 1 agrees with Rachel's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Salveen Richter of "Goldman Sachs" Maintained at Hold with Decreased Target to $5 on, Friday, February 16th, 2024
This is the rating of the analyst that currently disagrees with Rachel
- Mark Massaro of "BTIG" Maintained at Strong Buy with Decreased Target to $5 on, Thursday, April 4th, 2024
